To the Editor:
Dreyfuss and colleagues advocate the use of conventional amphotericin B (CAMB) for the treatment of life-threatening Candida infections in intensive care unit patients (1) . Key elements of their plea include the manageable toxicity associated with CAMB, using appropriate salt administration, hydration, continuous infusion, and electrolyte replacement; the lack of evidence that the newer formulations of AMB are more efficacious than CAMB; and financial considerations.
Dreyfuss and colleagues claim that continuous infusion of CAMB resulted in superior mortality compared with rapid infusion. The authors refer to two studies, but toxicity and not treatment efficacy was the primary focus in both (2, 3) . The first study was a prospective randomized trial comparing rapid infusion (4 h) with continuous infusion (24 h), aiming at inclusion of 40 patients in each category. The study was powered to detect a difference in creatinine clearance at the end of therapy. An analysis of treatment efficacy was provided using mortality, mortality due to invasive fungal infections, and breakthrough fungemia. A significant difference in efficacy was observed in favor of continuous CAMB infusion (2). However, this study was not blinded, indications for CAMB therapy included patients with an uncertain diagnosis of invasive fungal disease (i.e., possible invasive fungal disease and persistent fever), and all responding patients recovered from neutropenia as opposed to those who failed to CAMB therapy. In addition, a low number and wide variety of fungal infections were enrolled in the study including candidiasis, cryptococcosis, aspergillosis, and mucormycosis (2). The observed difference in mortality is at best "encouraging" as the authors themselves write in their discussion (2). The second study was a retrospective study comparing rapid infusion of CAMB in 42 patients (January 2001 to January 2002) with continuous infusion for 39 patients (January 2002 to January 2003) (3). A significant difference in mortality was again found in favor of the continuous infusion-treated patients. However, there were no significant differences in mortality due to invasive fungal infection or in breakthrough fungal infection between the two groups, suggesting that other factors might have contributed to the observed difference (3). We believe that these two studies do not provide sufficient clinical evidence to support the claim that the efficacy of continuous infusion of CAMB is superior to that of conventional rapid infusion. Even comparable efficacy between the two administration schedules has not been shown.
Our concern is underscored by preclinical studies that investigated the pharmacokinetics and pharmacodynamics of CAMB in invasive fungal infection. Experimental models of Candida infection show that the pharmacodynamic parameter that best correlated with outcome is the maximum concentration-tominimum inhibitory concentration (MIC) ratio [C max /MIC] (4). C max /MIC was also found to correlate best with efficacy in an in vivo model of Aspergillus infection (5). The aim therefore would be to achieve high peak serum concentrations of CAMB, which is best approached by rapid infusion, and not with continuous infusion. Lipid formulations of amphotericin B, such as liposomal amphotericin B, do allow higher peak concentrations to be achieved without dose-limiting renal toxicity.
When comparing the efficacy of CAMB with lipid formulations of the drug, the clinical trials were powered to demonstrate noninferiority, and as a consequence it would be very difficult to demonstrate superiority in any study arm. Also, hydration is considered the standard of care in centers where CAMB is administered through rapid infusion, as there is strong evidence that this provides renal protection.
Although some of us fall in the category of scientists with potential conflicts of interest, our scientific accuracy leads us to conclude that clinical evidence is lacking to justify continuous infusion of CAMB for treatment of life-threatening Candida infections. Our views are in keeping with recent major Candida practice guidelines (6) .
